News | February 03, 2009

Cerenis In-Licenses Technology for New Treatment of Aortic Valve Stenosis

February 3, 2009 - Cerenis Therapeutics SA, a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, has in-licensed intellectual property supporting an investigational new treatment of aortic valve stenosis (AVS) based on HDL therapy.

The intellectual property is based on breakthrough research from a team led by Jean-Claude Tardif, M.D. at the Montreal Heart Institute Research Centre, Canada.

AVS is characterized by a narrowing of the aortic valve, which can obstruct the flow of oxygenated blood from the heart to the rest of the body. As the heart works harder to compensate for the obstruction, the heart muscle thickens and can cause a potentially dangerous imbalance in blood pressure between the heart and body.

In Dr. Tardif's placebo-controlled study in rabbit AVS models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness was significantly decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group as well as reduced aortic valve calcification. Results of the study were published in April 2008 in the British Journal of Pharmacology.

For more information: www.cerenis.com.

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init